|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/191 | |
| A61K 31/201 | |||
| A61P 9/10 |
| (11) | Number of the document | 1696900 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04814462.0 |
| Date of filing the European patent application | 2004-12-16 | |
| (97) | Date of publication of the European application | 2006-09-06 |
| (45) | Date of publication and mention of the grant of the patent | 2010-07-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2004/042283 |
| Date | 2004-12-16 |
| (87) | Number | WO 2005/058303 |
| Date | 2005-06-30 |
| (30) | Number | Date | Country code |
| 529622 P | 2003-12-16 | US |
| (72) |
WADE, Michael, c/o United Therapeutics Corp., US
JEFFS, Roger A., c/o United Therapeutics Corp., US
ROSCIGNO, Robert, c/o United Therapeutics Corp., US
STROOTMAN, Deborah, c/o United Therapeutics, US
BRONSTEIN, Kathryn, US
|
| (73) |
United Therapeutics Corporation,
1040 Spring Street Silver Spring, Maryland 20910,
US
|
| (54) | USE OF TREPROSTINIL TO TREAT ISCHEMIC LESIONS |
| USE OF TREPROSTINIL TO TREAT ISCHEMIC LESIONS |